Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches
The therapeutic options in the treatment of cancer therapy have been recently significantly increased with systemic immune-targeted therapies. Novel immunotherapy approaches based on immune checkpoint blockade or engineered cytotoxic T lymphocytes have reached late-stage clinical development, with highly encouraging results. The success of cancer immunotherapy has generated a tremendous interest in further developing and exploring these strategies in combination with other approaches such as radiotherapy and local ablative therapies in oncology. The goal of this review is to discuss current approaches in immunotherapy and provide simple and constructive explanations on their mechanisms of action as well as certain more common and serious toxicities.
KeywordsCancer Immunotherapy Interventional radiology
Compliance with Ethical Standards
Conflict of interest
G. Coukos reports grants from Bristol‐Myers‐Squibb, Roche, the National Institutes of Health, Celgene and Boehringer–Ingelheim; personal fees from Roche and Genentech; and support for clinical trials from Bristol‐Myers‐Squibb, Merck and Roche. A. Denys is a contracted consultant for BTG, Farnham, UK. Patent WO 2012/073188 A1 was issued and licensed to BTG by A. Denys. K. Homicsko reports grant from Roche and is a consultant/advisory board member for BMS, Merck Serono, Roche and AMGEN. L.E. Kandalaft reports that she is a consultant/advisory board member of Geneos. A. Digklia and A. Hocquelet have nothing to disclose. R. Duran reports grant from BTG.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154–8.Google Scholar
- 10.Hickey RM, et al. Immuno-oncology and its opportunities for interventional radiologists: immune checkpoint inhibition and potential synergies with interventional oncology procedures. J Vasc Interv Radiol. 2017.Google Scholar
- 11.Robert C, Ghiringhelli F. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist. 2009;14:848–61.Google Scholar